Crossmark Global Holdings Inc. Increases Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Crossmark Global Holdings Inc. lifted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 11.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,935 shares of the medical equipment provider’s stock after purchasing an additional 510 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Lantheus were worth $542,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of LNTH. Farallon Capital Management LLC increased its holdings in Lantheus by 595.3% in the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after buying an additional 1,269,900 shares in the last quarter. Swedbank AB bought a new stake in Lantheus in the 1st quarter worth about $26,346,000. Vanguard Group Inc. increased its holdings in Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after buying an additional 389,828 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Lantheus in the 2nd quarter worth about $26,794,000. Finally, 2Xideas AG bought a new stake in shares of Lantheus during the 1st quarter valued at about $10,642,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. B. Riley boosted their price target on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Friday, November 8th. JMP Securities cut their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target for the company. Finally, Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Price Performance

NASDAQ LNTH opened at $76.83 on Friday. The company has a market cap of $5.34 billion, a PE ratio of 12.78 and a beta of 0.51. The stock’s 50 day simple moving average is $104.95 and its 200-day simple moving average is $96.44. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.